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BACKGROUND: Epithelial ovarian cancer (EOC) cells are prone to metastasise throughout the peritoneal cavity. The epithelial-
to-mesenchymal transition (EMT) is a necessary step towards metastatic tumour progression. CA125/MUC16 mucin is a high-
molecular-weight glycoprotein overexpressed in the majority of serous carcinomas, suggesting a possible role in the pathogenesis
of these cancers.
METHODS: The role of CA125/MUC16 in EMT was investigated using single-chain antibody-mediated knockdown of cell surface
CA125/MUC16 in overexpressing EOC NIH:OVCAR3 cells.
RESULTS: CA125/MUC16 knockdown was associated with morphological alterations along with decreased surface expression
of epithelial markers (E-cadherin, cytokeratin-18) and increased expression of mesenchymal markers (N-cadherin, vimentin).
Co-immunoprecipitation experiments revealed that CA125/MUC16 binds to E-cadherin and b-catenin complexes. The in vitro
studies showed disruption of cell–cell junctions, enhanced motility, migration and invasiveness in CA125/MUC16 knockdown cells.
Enhanced epidermal growth factor receptor (EGFR) activation was observed in CA125/MUC16 knockdown cells along with
increased Akt and ERK1/2 phosphorylation, which are downstream effectors of EGFR, and increased MMP-2 and MMP-9 expression
and activities. Epidermal growth factor receptor inhibition strongly inhibited the motility of CA125/MUC16 knockdown cells.
CONCLUSIONS: Our findings suggest that CA125/MUC16 plays a role in EMT, presumably through its interaction with E-cadherin and
b-catenin complexes and by modulating EGFR and its downstream signalling pathway in NIH:OVCAR3 cells.
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Epithelial ovarian carcinomas arise from the ovarian surface
epithelium (OSE) and account for the vast majority (480%) of
ovarian cancers (Ozols et al, 2004). Ovarian cancer is a highly
metastatic disease that primarily metastasises to the serosal
cavities, while dissemination through the vasculature is unusual
(Naora and Montell, 2005). Current treatments for patients with
metastatic ovarian carcinomas have limited efficacies with poor
5-year survival rates (Tingulstad et al, 2003). During the progres-
sion to a metastatic phenotype, carcinoma cells undergo morpho-
logical changes, become motile and acquire the ability to migrate
and invade to establish secondary tumours at distant sites. This
epithelial-to-mesenchymal transition (EMT) is characterised by
coordinated molecular and cellular changes, including a reduction
in cell–cell adhesion, the loss of apical–basolateral polarity, the
loss of epithelial markers and the gain of mesenchymal markers
(Hugo et al, 2007; Vergara et al, 2010). Epithelial-to-mesenchymal
transition is an important physiological process during embryo-
genesis and wound healing, but also a key step in cancer metastasis
(Radisky, 2005). Epithelial-to-mesenchymal transition occurs
during ovarian cancer progression in response to various stimuli.
A key feature of EMT is the switch from E-cadherin expression
at the cell surface to N-cadherin, which promotes the interaction
with stromal components (Cavallaro and Christofori, 2004).
CA125/MUC16 mucin is a high-molecular-weight glycoprotein
overexpressed in the majority of serous carcinomas, the most
common histological type of ovarian cancer, but is not detectable
in the epithelium of normal ovaries (Kabawat et al, 1983; Davis
et al, 1986; Nagata et al, 1991; De los Frailes et al, 1993; Kobayashi
et al, 1993). These observations suggest that CA125/MUC16 may
have a role in the pathogenesis of ovarian cancer. It was proposed
that CA125/MUC16 influences invasiveness of benign endo-
metriotic cell lines by acting as a chemoattractant (Gaetje et al,
1999). Rump et al (2004) reported that the interaction of CA125/
MUC16 with mesothelin mediates heterotypic cell adhesion and
suggested that CA125/MUC16 might contribute to the metastasis
of ovarian cancer. Patankar et al (2005) suggested that CA125/
MUC16 has potent suppression activity on natural killer cell.
Structurally, CA125/MUC16 is a type I transmembrane protein
consisting of an enormous N-terminal domain of more than 22000
amino-acid residues that are heavily glycosylated (O’Brien et al,
2001, 2002) with a carbohydrate content estimated to be up to 28%,
Received 18 October 2010; revised 14 January 2011; accepted 20
January 2011; published online 15 February 2011
*Correspondence: Dr A Piche ´; E-mail: alain.piche@usherbrooke.ca
British Journal of Cancer (2011) 104, 989–999
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swith O- and N-linked glycans (Kui et al, 2003). The CA125/MUC16
C-terminal domain is composed of an extracellular unique region
that contains a potential proteolytic cleavage site, a trans-
membrane domain and a short cytoplasmic tail with possible
phosphorylation sites (O’Brien et al, 2001, 2002).
This study was designed to assess the role of CA125/MUC16 in
EMT. Our results show an association between CA125/MUC16
knockdown and disruption of cell–cell junctions, enhanced
motility, migration and invasiveness in NIH:OVCAR3 cells. We
also show that CA125/MUC16 knockdown restores EGFR activa-
tion and its downstream signalling pathway in these cells.
MATERIALS AND METHODS
Cell culture and generation of CA125/MUC16 knockdown
in NIH:OVCAR3 cells
The single-chain variable fragment (scFv) was derived from the
hybridoma cell line VK-8 (kindly provided by KO Lloyd, Memorial
Sloan-Kettering Cancer Center, New York, NY, USA) (Lloyd et al,
1997), which expresses a monoclonal antibody against the
extracellular domain of CA125 tumour antigen, as described
previously (Boivin et al, 2009). The scFv DNA fragments were
cloned into the pLTR.KDEL retroviral plasmid in SfiI/NotI sites
after insertion of an SfiI/NotI containing polylinker at XhoI site of
pLTR.KDEL, which was used to generate NIH:OVCAR3 cells stably
expressing the CA125/MUC16 scFv. This vector targets the scFv to
the endoplasmic reticulum where the scFv antibody is retained,
thus preventing the cell surface localisation of CA125/MUC16.
Two independent clones were derived (1:9#7 and 1:9#9) and
were used for further studies. These clones displayed significant
downregulation of cell surface CA125/MUC16 (Boivin et al, 2009).
A control subline was also derived, which express an scFv that
does not bind CA125/MUC16. The human ovarian cancer cell
line NIH:OVCAR3 was obtained from the American Type Culture
Collection (Rockville, MD, USA) and grown in RPMI 1640 (Wisent,
St-Bruno, QC, Canada) supplemented with 20% FBS (Wisent),
2m ML -glutamine (Wisent), 100Uml
 1 penicillin, 100mgml
 1
streptomycin and 10mgml
 1 insulin (Wisent). Cells were main-
tained at 371C in humidified 5% CO2 incubators. NIH:OVCAR3
subclones were maintained in media with blasticidin 0.5–1mgml
 1
(Invitrogen, Burlington, ON, Canada). Fragments of the OSE were
scraped from the ovarian surface following a surgery procedure
for non-malignant gynaecological conditions. The fragments were
incubated in 4ml of OSE medium (Wisent) supplemented with
10% FBS and 10nM b-oestradiol in a T75 flask. Cells were washed
with 2ml of OSE medium. After 2 days, fresh OSE medium was
added and the medium was changed once in week after.
Reagents
Anti-E-cadherin antibody (clone 67A4) was from Chemicon
International Inc. (Billerica, MA, USA). Anti-claudin-7 (clone
5D10F3) and anti-cytokeratin 8–18 (clone zym5.2) antibodies
were from Zymed Laboratories Inc. (San Francisco, CA, USA).
Anti-tubulin antibody was from Sigma (Oakville, ON, Canada),
and anti-vimentin, anti-ERK1/2, anti-EGFR and anti-N-cadherin
antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA). Antibodies for Akt, ERK1/2 and EGFR were from Cell
Signaling (Pickering, ON, Canada). Antibodies for phospho-Akt
(Ser-473), phospho-EGFR (Y-1068) and phospho-ERK1/2 were
from Invitrogen. Anti-CA125 (M11) was from Dako (Burlington,
ON, Canada). Epidermal growth factor receptor inhibitors AG1478
and PD153035 were obtained from Calbiochem Corp. (La Jolla, CA,
USA). Epidermal growth factor was purchased from R&D Systems
(Minneapolis, MN, USA). Hepatocyte growth factor and TGF-b
were from PeproTech (Rocky Hill, NS, USA).
Immunoblot analysis
For the detection of phosphoproteins, cells were lysed in Nonidet
P-40 isotonic lysis buffer (283mM KCl, 10mM MgCl2,5 0 m M
HEPES, pH 7.2, 4mM EGTA, 0.5% NP-40, 10mM sodium fluoride,
100mM sodium pyrophosphate, 400mM sodium orthovanadate
with freshly added protease inhibitors (1mgml
 1 4-(2-aminoethyl)
benzenesulphonyl fluoride hydrochloride, 20mgml
 1 aprotinin,
0.7mgml
 1 pepstatin and 1mgml
 1 leupeptin) (Sigma)) and
proteins were quantified by Bradford assay (Bio-Rad, Hercules,
CA, USA). For the detection of other proteins, cells were lysed in
lysis buffer containing Triton X-100 (1%), 20mM Tris (pH 7.5),
150mM NaCl, 1mM EDTA and 1mM EGTA. Control and knock-
down cell lysates (equal amounts of proteins) were submitted to
SDS–PAGE electrophoresis and transferred onto PVDF membrane
(Roche, Laval, QC, Canada). The membranes were probed with N-
cadherin, vimentin, phospho-EGFR, EGFR, phospho-Akt, Akt,
phospho-ERK1/2, ERK1/2 or tubulin antibodies. Anti-mouse- and
anti-rabbit-conjugated HPR secondary antibodies were from Cell
Signaling. The immunoblots were developed by chemilumines-
cence using the ECL plus system according to the manufacturer’s
instruction (GE Healthcare, Baie d’Urfe ´, QC, Canada).
Immunofluorescence
Ovarian surface epithelium cells and stable NIH:OVCAR3 deriva-
tive sublines expressing the various scFvs were grown on glass
slides until a 50–70% confluence was reached. Glass slides were
then washed in cold PBS and cells fixed in 3.7% formaldehyde
for 15min on ice. Depending on the experiment, cells were
permeabilised with PBS containing 0.2% Triton X-100 for 20min
at room temperature. Slides were rinsed twice in PBS and blocked
in PBS/2% BSA at room temperature for 1h and then incu-
bated with primary antibodies in blocking buffer at room
temperature for 1h. Slides were washed two times in cold PBS,
incubated for 1h at room temperature with Alexa Fluor 594
(red) or Alexa Fluor 488 (green) F(ab0)2 fragment of goat anti-
mouse or goat anti-rabbit IgG (Invitrogen). In some experiments,
F-actin was visualised using phalloidin–rhodamine staining
(Sigma). After washing, slides were incubated for 2min in 40,
60-diamidino-2-phenylindole (DAPI) to visualise the nuclei,
washed again in PBS and mounted for visualisation by fluores-
cence microscopy with an Olympus IX70 (Olympus, Hamburg,
Germany).
Spheroid formation assay
Spheroid formation assays were performed with the parental cell
line, Ctrl scFv cells and CA125/MUC16 knockdown cells. A 25ml
drop of medium containing 5 10
3 cells was pipetted onto the
inner surface of a Petri dish lid. The lid was then placed on the
Petri dish so that the drops were hanging from the lid with the cells
suspended within them. To eliminate evaporation, 10ml serum-
free culture medium was placed in the bottom of the Petri dish.
After overnight incubation at 371C, the lid of the Petri dish was
inverted and photographed using an inverted tissue culture
microscope at  40 magnification.
Wound healing assay
Cells were seeded onto six-well plates and when they reached
100% confluence, a scratch was made across the cell mono-
layer. Cells were gently washed with PBS and new media
containing hydroxyurea 30mM (Sigma, Steinheim, Germany) were
added to block cell division. Cells were incubated for 24h and
photographed using an inverted tissue culture microscope at
 100 magnification.
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For motility assay, 5 10
3 cells were seeded in the top chamber of
monolayer-coated polyethylene terephthalate membranes (six-well
insert, pore size of 8mM) (Becton Dickinson, Mississauga, ON,
Canada). The cells were incubated for 16–20h, and cells that did
not migrate through the membrane were removed by scraping
with a cotton swab. Cells that migrated through the membrane
were fixed with methanol and stained with crystal violet 1% and
cells in 10 random fields were counted at  100 magnification.
For invasion assay, 5 10
3 cells were seeded on Matrigel-coated
membrane inserts (Becton Dickinson). The bottom chamber
contained 0.75ml RPMI supplemented with 10% foetal bovine
serum as a chemoattractant. Cells were incubated for 24h, the cells
remaining inside the insert were removed with a cotton swab and
cells that had penetrated the Matrigel to invade to the lower surface
of the membrane were fixed in methanol and stained with crystal
violet 1%. After air drying the membrane, the cells were counted at
 100 magnification in 10 random fields of view under a
microscope. Three independent experiments were performed in
each case.
Zymography
Matrix metalloproteinase-2 and MMP-9 activity in the conditioned
medium of parental NIH:OVCAR3, Ctrl scFv and CA125/MUC16
knockdown cells were analysed using 10% SDS gelatin zymo-
graphy. Cells were seeded in six-well plates and grown at a
density of 80% and cells were incubated for an additional 48h in
medium without FBS. Electrophoresis of conditioned medium
was performed in acrylamide gel containing 2mgml
 1 of gelatin.
After running, the gel was incubated for 3h in 0.25% Triton X-100
and the renaturing buffer was replaced with developing buffer
(Tris-HCl 50mM, NaCl 0.2M, CaCl2 5m M, Brij 35 0.02%) for
30min at room temperature. It was then replaced with fresh
developing buffer and the gel was incubated at 371C for 16h. The
gel was stained with Coomassie Blue R-250 to visualise protease
activity. Blood was used as a positive control for the activation of
these metalloproteinases.
Electronic microscopy
Cells were washed with cacodylate 0.1 M (pH 7.4) and fixed in 1.4%
glutaraldehyde at room temperature for 30min, and then in 2.5%
glutaraldehyde overnight at 41C. Cells were contrasted with 1%
osmium tetroxide and 1% uranyl acetate. Cells were dehydrated
in successive washes of 70, 90 and 100% ethanol before embedding
in EPON 3 X. Blocks were frozen onto mounting pins and
70–80nm sections were collected. Images were captured with a
transmission electron microscope (Hitachi H-7500) using AMT
Software (Boston, MA, USA).
Statistical analysis
Motility and invasion assay results were compared between the
parental cell line and Ctrl scFv and 1:9#7 and 1:9#9 knockdown
cells by the two-tailed Student’s t-test. A P-value of p0.05 was
considered statistically significant.
RESULTS
Morphological changes induced by the downregulation of
CA125/MUC16
We have chosen the widely used NIH:OVCAR3 epithelial ovarian
carcinoma cell line for our studies because, like most serous
ovarian carcinomas, these cells overexpress CA125/MUC16 at the
their surface and they show a complete epithelial phenotype
(Hamilton et al, 1983; Yin and Lloyd, 2001; Rump et al, 2004). In
addition, NIH:OVCAR3 cells are non-invasive in Boyden cham-
bers, poorly anchorage-independent, non-motile on plastic and do
not invade in collagen gels (Hamilton et al, 1987). These properties
make NIH:OVCAR3 cells ideally suitable to study EMT. To
overcome the difficulties associated with silencing the large size
of CA125/MUC16 RNA, we used a system where the cell surface
expression of CA125/MUC16 in NIH:OVCAR3 cells was down-
regulated by the expression of an endoplasmic reticulum-localised
CA125/MUC16 scFv to study its role in EMT (Gubbels et al, 2006;
Boivin et al, 2009). The expression of cell surface CA125/MUC16
was reduced by 90% in two independent NIH:OVCAR3 CA125/
MUC16 scFv-expressing subclones (1:9#7 and 1:9#9 scFvs),
whereas control NIH:OVCAR3 expressing a control (Ctrl) scFv
did not show alteration of CA125/MUC16 expression compared
with the parental NIH:OVCAR3 (Boivin et al, 2009). We noticed
that CA125/MUC16 knockdown in NIH:OVCAR3 cells display
significant changes in morphological features compared with
controls. Control cells (parental NIH:OVCAR3 and Ctrl scFv cells)
formed cobblestone-like monolayer, round boundary and cell–cell
junctions and adhesion between neighbouring cells (Figure 1A). In
contrast, knockdown cells have a longer and fibroblast-like shape
more characteristic of mesenchymal cells and display scattering
of the cells. These changes were compared with OSE cells that are
CA125/MUC16 negative and display mesenchymal features as
indicated by their fibroblast-like shape (Figure 1A). The distri-
bution of filamentous actin was analysed by phalloidin staining
and clearly revealed alterations in the actin cytoskeleton from
the predominance of cortical actin (control cells) into actin stress
fibres throughout the cells for CA125/MUC16 knockdown and
OSE cells (Figure 1B). Re-organisation of filamentous actin is
characteristic of a cell-spreading response (Cunningham et al,
1992). These observations suggest that the CA125/MUC16 knock-
down induces a phenotypic switch in carcinoma cells that resemble
OSE cells.
Next, the NIH:OVCAR3 sublines were plated under anchorage-
independent conditions and assessed, 48h later, for the formation
of cell spheroids that were visualised by phase-contrast micro-
scopy. As shown in Figure 1C, the Ctrl scFv-expressing cells and
parental NIH:OVCAR3 cells formed large floating spheroids,
whereas CA125/MUC16 knockdown cells appeared as single
isolated cells after 48h. Increasing the incubation time to 72h
did not allow the CA125/MUC16 knockdown cells to form cell
aggregates (data not shown). These findings show that the
downregulation of CA125/MUC16 cell surface expression prevents
homotypic cell aggregation and is associated with morphological
changes suggestive of EMT.
Expression of mesenchymal markers in CA125/MUC16
knockdown cells
Epithelial-to-mesenchymal transition is a process characterised by
the loss of epithelial markers such as E-cadherin and cytokeratin-18
and gain of mesenchymal markers such as N-cadherin and
vimentin (Thiery, 2003; Ahmed et al, 2007; Vergara et al, 2010).
During progression, carcinoma cells with increased invasiveness
and metastatic potential usually acquire mesenchymal markers
and show a reduction or absence of E-cadherin expression (Hugo
et al, 2007). However, in contrast to most adenocarcinomas,
advanced and poorly differentiated ovarian tumours continue to
express E-cadherin (Ahmed et al, 2007). This contrasts with OSE
cells, which do not express E-cadherin (Auersperg et al, 2001).
Immunofluorescence microscopy analysis showed that E-cadherin
was detected at the contacts between NIH:OVCAR3 control cells,
whereas there was a loss of E-cadherin staining at the cell surface
and an internalisation of E-cadherin in CA125/MUC16 knockdown
cells (Figure 2A). As expected, OSE did not express E-cadherin.
Knockdown cells behave very much like OSE cells; they displayed
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vimentin expression were increased compared with NIH:OVCAR3-
and Ctrl scFv-transfected cells (Figure 2A). Western blot analysis
confirmed the increased expression of N-cadherin and vimentin in
CA125/MUC16 knockdown cells (Figure 2B). The cytoplasmic
domain of E-cadherin has been shown to bind to b-catenin (Sasaki
et al, 2000). b-Catenin staining was observed to localise at the
contacts of cells in a manner similar to E-cadherin in NIH:
OVCAR3- and Ctrl scFv-transfected cells, but partially re-localised
in the cytoplasm in CA125/MUC16 knockdown cells (Figure 2C).
Altogether, these data show that CA125/MUC16 knockdown
induces a re-distribution of E-cadherin and b-catenin epithelial
markers throughout the cytoplasm and increased expression of
mesenchymal markers, such as N-cadherin and vimentin, con-
sistent with an EMT. The data also show that OVCAR3 knockdown
cells acquired a phenotype that was very similar to that of
CA125-negative OSE cells.
CA125/MUC16 binds to E-cadherin and b-catenin
complexes
As MUC1 has been previously shown to bind b-catenin
(Yamamoto et al, 1997), and as E-cadherin and b-catenin
expressions were altered by the knock down of CA125/MUC16,
we assessed whether these proteins associate with CA125/MUC16
in the presence or absence of EGF because EGF may affect
E-cadherin expression (Lu et al, 2003). Co-immunoprecipitation
experiments confirmed the association of CA125/MUC16 with
E-cadherin complexes in NIH:OVCAR3 cells. As shown in Figure 3A,
antibodies to CA125/MUC16 immunoprecipitated CA125/MUC16
from the lysates of NIH:OVCAR3 cells. More importantly,
E-cadherin was co-immunoprecipitated with CA125/MUC16 in these
cells with or without EGF treatment. In reciprocal experiments,
antibodies to E-cadherin immunoprecipitated E-cadherin and
co-immunoprecipitated CA125/MUC16 from the lysate of NIH:
OVCAR3 cells, suggesting that CA125/MUC16 forms complexes with
E-cadherin (Figure 3B). In a similar set of experiments, we found
that antibodies to b-catenin co-immunoprecipitated CA125/MUC16
(Figure 3C). These findings indicate that CA125/MUC16 associates
with E-cadherin and b-catenin complexes in NIH:OVCAR3 cells.
The knock down of CA125/MUC16 enhances migration
and disruption of cell–cell junctions of NIH:OVCAR3 cells
in vitro
Epithelial-to-mesenchymal transition is characterised by increased
motility and invasiveness (Hugo et al, 2007). To determine
whether CA125/MUC16 knockdown cells have acquired the ability
to migrate, we performed a wound healing assay in which the
motility of cells located at the edge of the wound was evaluated on
the basis of their ability to colonise the wounded area. In the
presence of serum (10% FBS) and hydroxyurea 30mM (to block
cell division), wound repair was observed only with the CA125/
MUC16 knockdown cells at 24h (Figure 4A). These results
were confirmed using a transwell chamber assay. As shown in
Figure 4B, a substantial number of CA125/MUC16 knockdown
cells migrated through the pores, whereas control cells did not
migrate at all.
Epithelial-to-mesenchymal transition usually involves the disrup-
tion of tight junctions, adherens junctions and desmosomes, which
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Figure 1 CA125/MUC16 knockdown alters cell morphology and spheroid formation of NIH:OVCAR3 cells. (A) The morphology of control, CA125/
MUC16 knockdown in NIH:OVCAR3 cells and OSE cells by phase-contrast microscopy ( 200 magnification). (B) Immunofluorescence analysis of control,
CA125/MUC16 knockdown cells and OSE cells ( 1000 magnification). The panels show phalloidin–rhodamine staining of actin-cytoskeleton changes
induced by CA125/MUC16 knockdown and DAPI for nuclear staining. (C) Control and knockdown cells were seeded in suspension for this aggregation
assay. Control cells showed bigger and tighter cell aggregates in contrast to knockdown cells ( 40 magnification).
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Because of the morphological changes and the absence of spheroid
formation in suspension observed in CA125/MUC16 knockdown
cells (Figure 1), and their enhanced potential to migrate (Figure 4),
we evaluated cell junctions by electronic microscopy in controls and
knockdown NIH:OVCAR3 cells. Figure 5A shows a representative
electron micrograph of three spot desmosomes between two Ctrl
scFv-expressing NIH:OVCAR3 cells forming adhering junctions. In
contrast, OSE and CA125/MUC16 knockdown cells lack such
adhering junctions, resulting in larger intercellular space. Consistent
with these results, the staining pattern for claudin-7 proteins, which
are involved in tight junctions, were altered in CA125/MUC16
knockdown cells as compared with control cells (Figure 5B).
Altogether, these data show that CA125/MUC16 knockdown in
NIH:OVCAR3 cells disrupts cell–cell junctions and promotes cell
migration.
The knock down of CA125/MUC16 induces an invasive
phenotype
The invasive ability of control and CA125/MUC16 knockdown cells
was examined by the transwell chamber assay containing an
extracellular matrix layer (Matrigel). As shown in Figure 6A,
CA125/MUC16 knockdown cells exhibited a significant increase in
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Figure 2 CA125/MUC16 knockdown alters expression of epithelial and mesenchymal markers. (A) Immunofluorescence analysis showing a decreased
or absence of cell surface expression of E-cadherin and cytokeratin-18 and increased expression of N-cadherin and vimentin in CA125/MUC16
knockdown and OSE cells ( 1000 magnification). (B) Immunoblot analysis of N-cadherin and vimentin expression in control and knockdown cells.
(C) Immunofluorescence analysis of b-catenin expression in control and CA125/MUC16 knockdown cells.
CA125/MUC16 knockdown induces EMT in ovarian cancer
M Comamala et al
993
British Journal of Cancer (2011) 104(6), 989–999 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sinvasion compared with control scFv-expressing cells and parental
NIH:OVCAR3 cells, which were unable to invade. Because the
downregulation of CA125/MUC16 in NIH:OVCAR3 cells was
associated with an invasive phenotype, we next investigated
whether knockdown cells show an induction of MMP activity, a
key event in the disruption of membranes for the invasion of
tumour cells (Suyama et al, 2002). Analysis of MMP levels in a
gelatin zymographic assay showed that the activity of pro-MMP2
and pro-MMP9 was substantially enhanced in knockdown cells
consistent with their greater capacity of invasion (Figure 6B).
These results indicate that the knock down of CA125/MUC16
promotes the ability of NIH:OVCAR3 cells to migrate and invade
as part of their EMT acquired phenotype.
The knock down of CA125/MUC16 EGFR restores its
downstream signalling
We analysed the mechanism of CA135/MUC16-induced EMT in
NIH:OVCAR3 cells. We observed an increase in the phosphory-
lation of EGFR (Y1068) in the CA125/MUC16 knockdown cells,
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Figure 4 CA125/MUC16 knockdown enhances cell motility. (A) Wound healing assay was performed as described in Materials and Methods to assess
the impact of CA125/MUC16 knockdown of cell motility ( 100 magnification). Upper panels show the initial wound and lower panels show the
same wound 24h later. (B) Boyden’s chamber motility assay for control and knockdown cells. Cell motility was significantly enhanced (Po0.001) in
CA125/MUC16 knockdown cells ( 100 magnification).
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Figure 3 Association of CA125/MUC16 with E-cadherin and b-catenin. Lysate from adherent NIH:OVCAR3 cells were immunoprecipitated with anti-
CA125/MUC16 (M11) antibody (A), anti-E-cadherin antibody (B) or anti-b-catenin antibody (C) in the presence or absence of EGF. Lysates were also
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were directly analysed by immunoblotting as controls (input).
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salthough the levels of total EGFR remained unchanged (Figure 7A).
We also determined the expression and phosphorylation of Akt
and ERK1/2, which are downstream signalling molecules induced
upon EGFR activation. CA125/MUC16 knockdown-induced acti-
vation of EGFR led to the activation of Akt and ERK1/2 as
shown in Figure 7A. These data suggest that the knock down of
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Figure 5 CA125/MUC16 knockdown disrupts cell–cell junctions. (A) Assessment of cell–cell junctions in Ctrl scFv and CA125/MUC16 knockdown cells
and OSE cells by electronic microscopy. Arrows indicate the presence of three desmosome spots in Ctrl scFv cells and the lack of such desmosomes in
knockdown cells (scale bar – 100nm). (B) Immunofluorescence analysis of claudin-7 expression, a protein involved in tight junctions, in Ctrl scFv and
knockdown cells showing the disruption of the protein at the cell surface of knockdown cells ( 1000 magnification).
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Figure 6 CA125/MUC16 knockdown increases the invasive phenotype. (A) Matrigel-coated Boyden’s chamber were used to assess the effect of CA125/
MUC16 knockdown on invasive property of NIH:OVCAR3. CA125/MUC16 knockdown cells exhibited a significant increase in invasiveness compared with
parental NIH:OVCAR3 and Ctrl scFv cells (Po0.001;  100 magnification). (B) Secreted MMP-2 and MMP-9 activities in cell-free conditioned medium is
increased in CA125/MUC16 knockdown cells compared with control NIH:OVCAR3 and Ctrl scFv cells. Blood was used as a positive control of MMP-2 and
MMP-9 activity.
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activation of its downstream targets to promote EMT.
Under physiological conditions, EMT of OSE cells is induced by
growth factors (Ahmed et al, 2006). For example, in primary
cultures of OSE cells, the addition of EGF induced morpho-
logical changes consistent with EMT and enhanced motility and
MMP-2/-9 activity (Ahmed et al, 2006). Furthermore, in prostate
cancer cells, EGF treatment can promote tumour cell motility
and invasion (Lu et al, 2003). Finally, the knock down of CA125/
MUC16 activates EGFR as described above. We thus examined the
ability of serum to induce a motile phenotype in the controls and
CA125/MUC16 knockdown cells using the wounding assay. As
shown in Figure 7B, when cells were incubated in the absence of
serum, no wound repair was observed in either control scFv or
1:9#9 scFv-expressing cells. Although the presence of serum (10%
FBS) also failed to promote wound repair in control scFv cells, it
strongly enhanced the motility of 1:9#9 scFv-expressing
cells (Figure 7B). In addition to EGF, other growth factors present
in the serum, such as TFG-b and HGF, have been involved in
promoting cell motility (Kalluri and Neilson, 2003). EGF treatment
(100ngml
 1), in the absence of serum, promoted wound repair of
1:9#9 scFv-expressing cells within 24h, whereas the motility of ctrl
scFv-expressing cells was not enhanced (Figure 7B). Similar
experiments carried out with HGF (20ngml
 1) or TGF-b
(10ngml
 1) in the absence of serum failed to promote wound
repair of 1:9#9 scFv-expressing cells (data not shown). Treatment
of 1:9#9 scFv-expressing cells with specific EGFR inhibitors
AG1478 and PD153035 resulted in the inhibition of EGF- and
serum-induced cell motility (Figure 7C). The stimulation of cell
motility by the serum in 1:9#9 scFv-expressing cells correlated
with EGFR activation and serum-induced EGFR activation was
blocked by AG1478 (Figure 7D). The results show that EGF is an
important component of serum that stimulates cell motility in
CA125/MUC16 knockdown cells.
DISCUSSION
Since it was first described in 1981 (Bast et al, 1981, 1983), the bio-
logical function of ovarian cancer tumour antigen CA125/MUC16
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Figure 7 CA125/MUC16 knockdown activates EGFR and its inhibition reduces the motility of these cells. (A) Western blot analysis showed activation of
EGFR and its downstream targets Akt and ERK1/2 in CA125/MUC16 knockdown cells as compared with NIH:OVCAR3 and Ctrl scFv cells. (B) Wound
healing assay in Ctrl scFv and CA125/MUC16 knockdown 1:9#9 cells in the presence or absence of serum (20% FBS). The migration of CA125/MUC16
knockdown cells was dependent on the presence of serum ( 100 magnification). (C) Wound healing assay in Ctrl scFv and CA125/MUC16 knockdown
1:9#9 cells treated with serum, EGF (10ngml
 1) and EGF inhibitors AG1478 (4mM) or PD153035 (5mM). EGF had an effect similar to serum on
the motility of CA125/MUC16 cells, but serum failed to stimulate migration in Ctrl scFv cells. The presence of EGF inhibitor strongly decreased serum-o r
EGF-induced motility in knockdown cells ( 100 magnification). (D) Western blot analysis of EGFR activation in Ctrl scFv and CA125/MUC16 knockdown
1:9#9 cells in the presence or absence of AG1478. AG1478 completely abrogated serum-mediated EGFR activation in knockdown cells.
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shas remained mostly unknown. Only recently, convincing evidence
showed that it binds to mesothelin (Rump et al, 2004) and
galectin-1 (Seelenmeyer et al, 2003). As these proteins are involved
in cell adhesion, one could speculate that CA125MUC16 is involved
in cell adhesion and perhaps participates to the metastatic process
of ovarian cancer. Altered expression of mucins such as MUC1 and
MUC4 has been shown to regulate various processes such as
tumour cell growth, cell adhesion, motility and tumorigenicity
(Wesseling et al, 1995; Satoh et al, 2000; Komatsu et al, 2001;
McDermott et al, 2001; Singh et al, 2004; Ponnusamy et al, 2010).
By analogy with these mucins, it may be expected that
CA125MUC16 plays similar functions in ovarian cancer. However,
direct experimental evidences until now were lacking to support
such roles. In this study, we provide evidence that CA125/MUC16
affects cellular behaviours in NIH:OVCAR3 cells, including
changes in morphology and motility. At the molecular level, the
knock down of CA125/MUC16 induces significant alteration of
EMT markers. In addition, CA125/MUC16 knockdown activates
EGFR and its downstream targets Akt and ERK1/2 to promote cell
motility. Furthermore, the knock down of CA125/MUC16 pro-
moted cell migration and invasion of NIH:OVCAR3 cells. To the
best of our knowledge, this is the first report showing the role of
CA125/MUC16 in EMT.
Ovarian cancer cells are prone to metastasise throughout the
peritoneal cavity. Metastasis is a complex process involving
changes in cell–extracellular matrix and cell–cell junctions.
Epithelial-to-mesenchymal transition is a necessary step towards
metastatic tumour progression during detachment of tumour cells
from the primary tumour site and attachment to metastatic sites.
Epithelial-to-mesenchymal transition results in enhanced cell
motility and invasion. Few studies have examined the factors that
promote EMT of epithelial ovarian cancer (EOC) cells (Rosano
et al, 2005; Theriault et al, 2007; Pon et al, 2008). Here we show
that CA125/MUC16 cell surface knockdown induces EMT in
NIH:OVCAR3 cells. During progression, EOC cells tend to detach
from each other and disseminate within the peritoneal cavity.
Our data suggest that CA125/MUC16 could be involved in this
process. Interestingly, we showed that CA125/MUC16 knockdown
induces an intracellular relocalisation of E-cadherin (Figure 2A).
The re-distribution of E-cadherin in the cytoplasm, the decreased
expression of cytokeratin-18 and the gain of mesenchymal
markers N-cadherin and vimentin are the hallmarks of EMT
(Thiery, 2003). Ovarian carcinoma are unique in that epithelial
differentiation becomes more, rather than less, prominent as the
tumour develop. This increased epithelial differentiation is
associated with an increase in E-cadherin expression. However,
despite the fact that ovarian tumours express E-cadherin, ovarian
carcinoma metastases often show the absence of E-cadherin
expression, suggesting that the loss of E-cadherin is associated
with the ability of ovarian tumour to metastasise (Sundfeldt, 2003).
Similarly, the loss of tissue CA125/MUC16 expression is associated
with late-stage EOC tumour (Hogdall et al, 2007). It is possible that
binding of CA125/MUC16 to E-cadherin complexes results in the
surface localisation of E-cadherin, which mediates cell contact
and suppression of cell invasion. Conversely, in the absence of
CA125/MUC16, E-cadherin relocalises in the cytoplasm, which
abolishes its ability to promote cell contact formation. This is
supported by the observations that CA125/MUC16 associates with
E-cadherin complexes (Figure 3), the fact that knock down of
CA125/MUC16 induces E-cadherin relocalisation in the cytoplasm
(Figure 2A) and that E-cadherin relocalisation in knock-
down NIH:OVCAR3 cells is associated with increased motility
(Figure 4). Our data also show that CA125/MUC16 forms
complexes with b-catenin. The cytoplasmic domain of E-cadherin
binds to b-catenin, which forms complexes with a-catenin (Ozawa
et al, 1990), actin (Adams et al, 1996), p120 (Staddon et al, 1995),
EGFR (Hoschuetzky et al, 1994) and other proteins. It is possible
that by forming a complex with E-cadherin and/or b-catenin,
CA125/MUC16 could re-distribute EGFR and consequently modu-
lates its signalling pathway.
CA125/MUC16 tandem repeats were identified as interacting
with mesothelin and that this interaction mediates binding of cells
expressing CA125/MUC16 tandem repeats to mesothelial cells or
mesothelin-expressing cells. CA125/MUC16 may be involved in
metastasis of ovarian cancers by mediating cell attachment to
mesothelial cells of the peritoneal lining (Rump et al, 2004).
The results presented herein are consistent with this report and
the suggestion that CA125/MUC16 modulates cell adhesion
properties. However, based on the approach used to downregulate
CA125/MUC16, it is impossible to assign a specific role to the
large N-terminal domain of CA125/MUC16 in regulating the EMT
process.
CA125/MUC16 is a serum marker that is elevated in more than
80% of EOC patients (Canney et al, 1984; Vergote et al, 1987). In a
recent study, the loss of tissue CA125/MUC16 was associated
with late-stage primary EOC tumour. Furthermore, the loss of
CA125/MUC16 expression significantly correlated with poor
survival (Hogdall et al, 2007). The demonstration that down-
regulation of cell surface CA125/MUC16 in NIH:OVCAR3 cells
results in increased motility and invasion is therefore consistent
with these findings. The loss of cell surface CA125/MUC16 in late-
stage tumours could enhance their ability to metastasise. Although
little is known about the signalling pathways regulated by CA125/
MUC16, its downregulation was associated with the upregulation
of N-cadherin and vimentin, two well-established mesenchymal
markers. Whether CA125/MUC16 directly regulates the expression
of these mesenchymal markers remains to be determined.
However, a recent study showed that MUC4 modulates N-cadherin
expression in an FAK-dependent manner in a pancreatic cell line
(Shintani et al, 2008). Furthermore, Huang et al (2005) showed
that MUC1 cytoplasmic domain binds b-catenin and can therefore
compete with E-cadherin for binding to b-catenin.
The OSE is a major target tissue for ovarian carcinoma
formation. With each ovulation, OSE cells become highly
migratory so that they can fill the large wound that is generated
during oocyte release. This phenotypic switch to a mesenchymal,
non-cohesive migratory phenotype also occurs when normal
human OSE cells are explanted into monolayer culture, which
likely reflects a primitive differentiation state that may be
facilitated by an absence of E-cadherin and/or CA125/MUC16 in
these cells (Auersperg et al, 2001). In contrast, well-differentiated
EOC are non-migratory and they express CA125/MUC16 and
E-cadherin at their cell surface. Therefore, cell surface expression
of E-cadherin and CA125/MUC16 may be functionally important
during ovarian carcinoma formation. Indeed, ectopic expression
of E-cadherin in OSE cells induces a phenotypic switch from
mesenchymal-to-epithelial-like properties (Wu et al, 2008).
Furthermore, our data showed that CA125/MUC16 knock-
down in OVCAR3 cells, which is associated with the loss of cell
surface E-cadherin expression, induced a switch from epithelial-
to-mesenchymal features. Thus, CA125/MUC16 knockdown in
OVCAR3 cells behave like CA125/MUC16-negative OSE cells with
regard to EMT markers.
On the basis of the previous finding of EGF-induced EMT in
human OSE (Ahmed et al, 2006), we characterised the mechanism
underlying CA125/MUC16-induced EMT by showing that CA125/
MUC16 knockdown activates EGFR and its downstream signalling
in NIH:OVCAR3 cells. We observed an increase in the activation of
Akt, ERK1/2 and MMP-2 and MMP-9 in CA125/MUC16 knock-
down cells. Activation of the MAPK-ERK pathway has been shown
to upregulate MMP-9 and enhanced cell migration (Suyama et al,
2002). In NIH:OVCAR3 cells, the increased phosphorylation of
ERK1/2 induced by the knockdown of CA125/MUC16 may lead
to MMP-9 increased activity and invasiveness. Akt activation has
been associated with the induction of EMT in carcinoma cells
(Grille et al, 2003; Yan et al, 2009). These data are consistent with
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finding provides mechanistic support to a previous study, which
showed that CA125/MUC16 tissue loss (extracellular region) is
associated with poor prognosis in EOC (Hogdall et al, 2007).
In conclusion, we provide direct evidence that the knockdown
of CA125/MUC16 in NIH:OVCAR3 ovarian cancer cells alters
epithelial and mesenchymal markers, cell motility and migration.
The underlying mechanism involves, at least in part, the activation
of EGFR and its downstream signalling pathway.
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